Kim A Papp, Andrew Blauvelt, Michael Bukhalo, Melinda Gooderham, James G Krueger, Jean-Philippe Lacour, Alan Menter, Sandra Philipp, Howard Sofen, Stephen Tyring, Beate R Berner, Sudha Visvanathan, Chandrasena Pamulapati, Nathan Bennett, Mary Flack, Paul Scholl, Steven J Padula. N Engl J Med 2017
Times Cited: 285
Times Cited: 285
Times Cited
Times Co-cited
Similarity
Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis.
Yaowei Zhu, Chuanpu Hu, Ming Lu, Sam Liao, Joseph C Marini, Jennifer Yohrling, Newman Yeilding, Hugh M Davis, Honghui Zhou. J Clin Pharmacol 2009
Yaowei Zhu, Chuanpu Hu, Ming Lu, Sam Liao, Joseph C Marini, Jennifer Yohrling, Newman Yeilding, Hugh M Davis, Honghui Zhou. J Clin Pharmacol 2009
5
Comparative efficacy and safety of thirteen biologic therapies for patients with moderate or severe psoriasis: A network meta-analysis.
Guomei Xu, Meng Xia, Chenjie Jiang, Ying Yu, Guomi Wang, Jiaojiao Yuan, Xingwu Duan. J Pharmacol Sci 2019
Guomei Xu, Meng Xia, Chenjie Jiang, Ying Yu, Guomi Wang, Jiaojiao Yuan, Xingwu Duan. J Pharmacol Sci 2019
26
Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial.
U Chaudhari, P Romano, L D Mulcahy, L T Dooley, D G Baker, A B Gottlieb. Lancet 2001
U Chaudhari, P Romano, L D Mulcahy, L T Dooley, D G Baker, A B Gottlieb. Lancet 2001
5
A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R.
Christi Parham, Madaline Chirica, Jacqueline Timans, Elena Vaisberg, Marilyn Travis, Jeanne Cheung, Stefan Pflanz, Rebecca Zhang, Komal P Singh, Felix Vega,[...]. J Immunol 2002
Christi Parham, Madaline Chirica, Jacqueline Timans, Elena Vaisberg, Marilyn Travis, Jeanne Cheung, Stefan Pflanz, Rebecca Zhang, Komal P Singh, Felix Vega,[...]. J Immunol 2002
5
Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J).
Hidehisa Saeki, Hidemi Nakagawa, Ko Nakajo, Taeko Ishii, Yoji Morisaki, Takehiro Aoki, Gregory S Cameron, Olawale O Osuntokun. J Dermatol 2017
Hidehisa Saeki, Hidemi Nakagawa, Ko Nakajo, Taeko Ishii, Yoji Morisaki, Takehiro Aoki, Gregory S Cameron, Olawale O Osuntokun. J Dermatol 2017
5
The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study.
Jerry Bagel, Kristina Callis Duffin, Angela Moore, Laura K Ferris, Kimberly Siu, Jennifer Steadman, Farid Kianifard, Judit Nyirady, Mark Lebwohl. J Am Acad Dermatol 2017
Jerry Bagel, Kristina Callis Duffin, Angela Moore, Laura K Ferris, Kimberly Siu, Jennifer Steadman, Farid Kianifard, Judit Nyirady, Mark Lebwohl. J Am Acad Dermatol 2017
9
Adalimumab for the treatment of moderate to severe psoriasis: subanalysis of effects on scalp and nails in the BELIEVE study.
D Thaçi, K Unnebrink, M Sundaram, S Sood, Y Yamaguchi. J Eur Acad Dermatol Venereol 2015
D Thaçi, K Unnebrink, M Sundaram, S Sood, Y Yamaguchi. J Eur Acad Dermatol Venereol 2015
10
How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review.
Phyllis I Spuls, Lidian L A Lecluse, Marie-Louise N F Poulsen, Jan D Bos, Robert S Stern, Tamar Nijsten. J Invest Dermatol 2010
Phyllis I Spuls, Lidian L A Lecluse, Marie-Louise N F Poulsen, Jan D Bos, Robert S Stern, Tamar Nijsten. J Invest Dermatol 2010
5
Pivotal role of dermal IL-17-producing γδ T cells in skin inflammation.
Yihua Cai, Xiaoyan Shen, Chuanlin Ding, Chunjian Qi, Kejia Li, Xia Li, Venkatakrishna R Jala, Huang-ge Zhang, Tian Wang, Jie Zheng,[...]. Immunity 2011
Yihua Cai, Xiaoyan Shen, Chuanlin Ding, Chunjian Qi, Kejia Li, Xia Li, Venkatakrishna R Jala, Huang-ge Zhang, Tian Wang, Jie Zheng,[...]. Immunity 2011
5
Moderate to severe plaque psoriasis with scalp involvement: a randomized, double-blind, placebo-controlled study of etanercept.
Jerry Bagel, Charles Lynde, Stephen Tyring, Gregory Kricorian, Yifei Shi, Paul Klekotka. J Am Acad Dermatol 2012
Jerry Bagel, Charles Lynde, Stephen Tyring, Gregory Kricorian, Yifei Shi, Paul Klekotka. J Am Acad Dermatol 2012
6
Risk of myocardial infarction in patients with psoriasis.
Joel M Gelfand, Andrea L Neimann, Daniel B Shin, Xingmei Wang, David J Margolis, Andrea B Troxel. JAMA 2006
Joel M Gelfand, Andrea L Neimann, Daniel B Shin, Xingmei Wang, David J Margolis, Andrea B Troxel. JAMA 2006
4
Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years.
Christopher E M Griffiths, Kim A Papp, Alexa B Kimball, Bruce Randazzo, Michael Song, Shu Li, Yaung-Kaung Shen, Andrew Blauvelt. J Drugs Dermatol 2018
Christopher E M Griffiths, Kim A Papp, Alexa B Kimball, Bruce Randazzo, Michael Song, Shu Li, Yaung-Kaung Shen, Andrew Blauvelt. J Drugs Dermatol 2018
15
Definition of treatment goals for moderate to severe psoriasis: a European consensus.
U Mrowietz, K Kragballe, K Reich, P Spuls, C E M Griffiths, A Nast, J Franke, C Antoniou, P Arenberger, F Balieva,[...]. Arch Dermatol Res 2011
U Mrowietz, K Kragballe, K Reich, P Spuls, C E M Griffiths, A Nast, J Franke, C Antoniou, P Arenberger, F Balieva,[...]. Arch Dermatol Res 2011
4
Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1).
J Barker, M Hoffmann, G Wozel, J-P Ortonne, H Zheng, H van Hoogstraten, K Reich. Br J Dermatol 2011
J Barker, M Hoffmann, G Wozel, J-P Ortonne, H Zheng, H van Hoogstraten, K Reich. Br J Dermatol 2011
4
Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study.
Kim Papp, Herve Bachelez, Antonio Costanzo, Peter Foley, Melinda Gooderham, Primal Kaur, Joanna Narbutt, Sandra Philipp, Lynda Spelman, Jolanta Weglowska,[...]. J Am Acad Dermatol 2017
Kim Papp, Herve Bachelez, Antonio Costanzo, Peter Foley, Melinda Gooderham, Primal Kaur, Joanna Narbutt, Sandra Philipp, Lynda Spelman, Jolanta Weglowska,[...]. J Am Acad Dermatol 2017
5
Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE).
Ulrich Mrowietz, Craig L Leonardi, Giampiero Girolomoni, Darryl Toth, Akimichi Morita, Shyamal A Balki, Jacek C Szepietowski, Pascaline Regnault, Helen Thurston, Charis Papavassilis. J Am Acad Dermatol 2015
Ulrich Mrowietz, Craig L Leonardi, Giampiero Girolomoni, Darryl Toth, Akimichi Morita, Shyamal A Balki, Jacek C Szepietowski, Pascaline Regnault, Helen Thurston, Charis Papavassilis. J Am Acad Dermatol 2015
4
The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis.
C E M Griffiths, D Thaçi, S Gerdes, P Arenberger, G Pulka, K Kingo, J Weglowska, N Hattebuhr, J Poetzl, H Woehling,[...]. Br J Dermatol 2017
C E M Griffiths, D Thaçi, S Gerdes, P Arenberger, G Pulka, K Kingo, J Weglowska, N Hattebuhr, J Poetzl, H Woehling,[...]. Br J Dermatol 2017
4
Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial.
Mamitaro Ohtsuki, Yukari Okubo, Mayumi Komine, Shinichi Imafuku, Robert M Day, Peng Chen, Rosemary Petric, Allan Maroli, Osamu Nemoto. J Dermatol 2017
Mamitaro Ohtsuki, Yukari Okubo, Mayumi Komine, Shinichi Imafuku, Robert M Day, Peng Chen, Rosemary Petric, Allan Maroli, Osamu Nemoto. J Dermatol 2017
10
An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Richard B Warren, Ulrich Mrowietz, Ralph von Kiedrowski, Johannes Niesmann, Dagmar Wilsmann-Theis, Kamran Ghoreschi, Ina Zschocke, Thomas M Falk, Norbert Blödorn-Schlicht, Kristian Reich. Lancet 2017
Richard B Warren, Ulrich Mrowietz, Ralph von Kiedrowski, Johannes Niesmann, Dagmar Wilsmann-Theis, Kamran Ghoreschi, Ina Zschocke, Thomas M Falk, Norbert Blödorn-Schlicht, Kristian Reich. Lancet 2017
7
A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis.
K A Papp, M A Menter, M Raman, D Disch, D E Schlichting, C Gaich, W Macias, X Zhang, J M Janes. Br J Dermatol 2016
K A Papp, M A Menter, M Raman, D Disch, D E Schlichting, C Gaich, W Macias, X Zhang, J M Janes. Br J Dermatol 2016
4
Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis.
Kristian Reich, Kim A Papp, Robert T Matheson, John H Tu, Robert Bissonnette, Marc Bourcier, David Gratton, Rodion A Kunynetz, Yves Poulin, Les A Rosoph,[...]. Exp Dermatol 2015
Kristian Reich, Kim A Papp, Robert T Matheson, John H Tu, Robert Bissonnette, Marc Bourcier, David Gratton, Rodion A Kunynetz, Yves Poulin, Les A Rosoph,[...]. Exp Dermatol 2015
4
Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial.
Séverine Vermeire, William J Sandborn, Silvio Danese, Xavier Hébuterne, Bruce A Salzberg, Maria Klopocka, Dino Tarabar, Tomas Vanasek, Miloš Greguš, Paul A Hellstern,[...]. Lancet 2017
Séverine Vermeire, William J Sandborn, Silvio Danese, Xavier Hébuterne, Bruce A Salzberg, Maria Klopocka, Dino Tarabar, Tomas Vanasek, Miloš Greguš, Paul A Hellstern,[...]. Lancet 2017
4
Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.
Iain B McInnes, Arthur Kavanaugh, Alice B Gottlieb, Lluís Puig, Proton Rahman, Christopher Ritchlin, Carrie Brodmerkel, Shu Li, Yuhua Wang, Alan M Mendelsohn,[...]. Lancet 2013
Iain B McInnes, Arthur Kavanaugh, Alice B Gottlieb, Lluís Puig, Proton Rahman, Christopher Ritchlin, Carrie Brodmerkel, Shu Li, Yuhua Wang, Alan M Mendelsohn,[...]. Lancet 2013
4
Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways.
Rajan P Nair, Kristina Callis Duffin, Cynthia Helms, Jun Ding, Philip E Stuart, David Goldgar, Johann E Gudjonsson, Yun Li, Trilokraj Tejasvi, Bing-Jian Feng,[...]. Nat Genet 2009
Rajan P Nair, Kristina Callis Duffin, Cynthia Helms, Jun Ding, Philip E Stuart, David Goldgar, Johann E Gudjonsson, Yun Li, Trilokraj Tejasvi, Bing-Jian Feng,[...]. Nat Genet 2009
4
Th17 Cell Pathway in Human Immunity: Lessons from Genetics and Therapeutic Interventions.
Dhavalkumar D Patel, Vijay K Kuchroo. Immunity 2015
Dhavalkumar D Patel, Vijay K Kuchroo. Immunity 2015
4
Ulcerative colitis.
Ryan Ungaro, Saurabh Mehandru, Patrick B Allen, Laurent Peyrin-Biroulet, Jean-Frédéric Colombel. Lancet 2017
Ryan Ungaro, Saurabh Mehandru, Patrick B Allen, Laurent Peyrin-Biroulet, Jean-Frédéric Colombel. Lancet 2017
4
IL-23 promotes tumour incidence and growth.
John L Langowski, Xueqing Zhang, Lingling Wu, Jeanine D Mattson, Taiying Chen, Kathy Smith, Beth Basham, Terrill McClanahan, Robert A Kastelein, Martin Oft. Nature 2006
John L Langowski, Xueqing Zhang, Lingling Wu, Jeanine D Mattson, Taiying Chen, Kathy Smith, Beth Basham, Terrill McClanahan, Robert A Kastelein, Martin Oft. Nature 2006
4
Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies.
K Reich, K A Papp, A W Armstrong, Y Wasfi, S Li, Y K Shen, B Randazzo, M Song, A B Kimball. Br J Dermatol 2019
K Reich, K A Papp, A W Armstrong, Y Wasfi, S Li, Y K Shen, B Randazzo, M Song, A B Kimball. Br J Dermatol 2019
10
The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials.
H C Bucher, G H Guyatt, L E Griffith, S D Walter. J Clin Epidemiol 1997
H C Bucher, G H Guyatt, L E Griffith, S D Walter. J Clin Epidemiol 1997
4
A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial.
Philip J Mease, Josef S Smolen, Frank Behrens, Peter Nash, Soyi Liu Leage, Lingnan Li, Hasan Tahir, Melinda Gooderham, Eswar Krishnan, Hong Liu-Seifert,[...]. Ann Rheum Dis 2020
Philip J Mease, Josef S Smolen, Frank Behrens, Peter Nash, Soyi Liu Leage, Lingnan Li, Hasan Tahir, Melinda Gooderham, Eswar Krishnan, Hong Liu-Seifert,[...]. Ann Rheum Dis 2020
4
Long-term efficacy and safety of secukinumab in Japanese patients with moderate to severe plaque psoriasis: 3-year results of a double-blind extension study.
Yukari Okubo, Mamitaro Ohtsuki, Akimichi Morita, Masako Yamaguchi, Tomohiro Shima, Yumiko Tani, Hidemi Nakagawa. J Dermatol 2019
Yukari Okubo, Mamitaro Ohtsuki, Akimichi Morita, Masako Yamaguchi, Tomohiro Shima, Yumiko Tani, Hidemi Nakagawa. J Dermatol 2019
30
Long-term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open-label extension study.
K Papp, A Menter, Y Poulin, Y Gu, E H Sasso. J Eur Acad Dermatol Venereol 2013
K Papp, A Menter, Y Poulin, Y Gu, E H Sasso. J Eur Acad Dermatol Venereol 2013
9
Shifting the focus - the primary role of IL-23 in psoriasis and other inflammatory disorders.
M J Gooderham, K A Papp, C W Lynde. J Eur Acad Dermatol Venereol 2018
M J Gooderham, K A Papp, C W Lynde. J Eur Acad Dermatol Venereol 2018
9
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.
Dominique Baeten, Joachim Sieper, Jürgen Braun, Xenofon Baraliakos, Maxime Dougados, Paul Emery, Atul Deodhar, Brian Porter, Ruvie Martin, Mats Andersson,[...]. N Engl J Med 2015
Dominique Baeten, Joachim Sieper, Jürgen Braun, Xenofon Baraliakos, Maxime Dougados, Paul Emery, Atul Deodhar, Brian Porter, Ruvie Martin, Mats Andersson,[...]. N Engl J Med 2015
4
Therapeutic Targeting of IL-17 and IL-23 Cytokines in Immune-Mediated Diseases.
George E Fragoulis, Stefan Siebert, Iain B McInnes. Annu Rev Med 2016
George E Fragoulis, Stefan Siebert, Iain B McInnes. Annu Rev Med 2016
4
Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages.
Laurie E Harrington, Robin D Hatton, Paul R Mangan, Henrietta Turner, Theresa L Murphy, Kenneth M Murphy, Casey T Weaver. Nat Immunol 2005
Laurie E Harrington, Robin D Hatton, Paul R Mangan, Henrietta Turner, Theresa L Murphy, Kenneth M Murphy, Casey T Weaver. Nat Immunol 2005
4
IL-12 family cytokines: immunological playmakers.
Dario A A Vignali, Vijay K Kuchroo. Nat Immunol 2012
Dario A A Vignali, Vijay K Kuchroo. Nat Immunol 2012
4
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update.
Laure Gossec, Xenofon Baraliakos, Andreas Kerschbaumer, Maarten de Wit, Iain McInnes, Maxime Dougados, Jette Primdahl, Dennis G McGonagle, Daniel Aletaha, Andra Balanescu,[...]. Ann Rheum Dis 2020
Laure Gossec, Xenofon Baraliakos, Andreas Kerschbaumer, Maarten de Wit, Iain McInnes, Maxime Dougados, Jette Primdahl, Dennis G McGonagle, Daniel Aletaha, Andra Balanescu,[...]. Ann Rheum Dis 2020
4
The immunogenetics of Psoriasis: A comprehensive review.
Jamie L Harden, James G Krueger, Anne M Bowcock. J Autoimmun 2015
Jamie L Harden, James G Krueger, Anne M Bowcock. J Autoimmun 2015
4
Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation.
Craig A Murphy, Claire L Langrish, Yi Chen, Wendy Blumenschein, Terrill McClanahan, Robert A Kastelein, Jonathon D Sedgwick, Daniel J Cua. J Exp Med 2003
Craig A Murphy, Claire L Langrish, Yi Chen, Wendy Blumenschein, Terrill McClanahan, Robert A Kastelein, Jonathon D Sedgwick, Daniel J Cua. J Exp Med 2003
4
Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Fan Bai, Gang Gang Li, Qingmin Liu, Xinwu Niu, Ruilian Li, Huiqun Ma. J Immunol Res 2019
Fan Bai, Gang Gang Li, Qingmin Liu, Xinwu Niu, Ruilian Li, Huiqun Ma. J Immunol Res 2019
6
Economic Burden of Psoriasis in the United States: A Systematic Review.
Elizabeth A Brezinski, Jaskaran S Dhillon, April W Armstrong. JAMA Dermatol 2015
Elizabeth A Brezinski, Jaskaran S Dhillon, April W Armstrong. JAMA Dermatol 2015
4
Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial.
Atul Deodhar, Philip S Helliwell, Wolf-Henning Boehncke, Alexa P Kollmeier, Elizabeth C Hsia, Ramanand A Subramanian, Xie L Xu, Shihong Sheng, Prasheen Agarwal, Bei Zhou,[...]. Lancet 2020
Atul Deodhar, Philip S Helliwell, Wolf-Henning Boehncke, Alexa P Kollmeier, Elizabeth C Hsia, Ramanand A Subramanian, Xie L Xu, Shihong Sheng, Prasheen Agarwal, Bei Zhou,[...]. Lancet 2020
4
Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics.
Philip J Mease, Dafna D Gladman, Kim A Papp, Majed M Khraishi, Diamant Thaçi, Frank Behrens, Robert Northington, Joanne Fuiman, Eustratios Bananis, Robert Boggs,[...]. J Am Acad Dermatol 2013
Philip J Mease, Dafna D Gladman, Kim A Papp, Majed M Khraishi, Diamant Thaçi, Frank Behrens, Robert Northington, Joanne Fuiman, Eustratios Bananis, Robert Boggs,[...]. J Am Acad Dermatol 2013
4
Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.
Alice Gottlieb, Alan Menter, Alan Mendelsohn, Yaung-Kaung Shen, Shu Li, Cynthia Guzzo, Scott Fretzin, Rod Kunynetz, Arthur Kavanaugh. Lancet 2009
Alice Gottlieb, Alan Menter, Alan Mendelsohn, Yaung-Kaung Shen, Shu Li, Cynthia Guzzo, Scott Fretzin, Rod Kunynetz, Arthur Kavanaugh. Lancet 2009
4
A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
A Blauvelt, K Papp, A Gottlieb, A Jarell, K Reich, C Maari, K B Gordon, L K Ferris, R G Langley, Y Tada,[...]. Br J Dermatol 2020
A Blauvelt, K Papp, A Gottlieb, A Jarell, K Reich, C Maari, K B Gordon, L K Ferris, R G Langley, Y Tada,[...]. Br J Dermatol 2020
10
Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis.
Richard B Warren, Melinda Gooderham, Russel Burge, Baojin Zhu, David Amato, Karen Huayu Liu, David Shrom, Jiaying Guo, Alan Brnabic, Andrew Blauvelt. J Am Acad Dermatol 2020
Richard B Warren, Melinda Gooderham, Russel Burge, Baojin Zhu, David Amato, Karen Huayu Liu, David Shrom, Jiaying Guo, Alan Brnabic, Andrew Blauvelt. J Am Acad Dermatol 2020
17
Efficacy of several biological therapies for treating moderate to severe psoriasis: A network meta-analysis.
Wenjun Geng, Jianhua Zhao, Jixing Fu, Huamin Zhang, Shaohua Qiao. Exp Ther Med 2018
Wenjun Geng, Jianhua Zhao, Jixing Fu, Huamin Zhang, Shaohua Qiao. Exp Ther Med 2018
30
Safety and efficacy of guselkumab in Japanese patients with moderate-to-severe plaque psoriasis: a randomized, placebo-controlled, ascending-dose study.
O Nemoto, K Hirose, S Shibata, K Li, H Kubo. Br J Dermatol 2018
O Nemoto, K Hirose, S Shibata, K Li, H Kubo. Br J Dermatol 2018
16
Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.